Stockscreener 앱 받기
38.28
2.01%
-0.785
전일 마감가:
$39.07
열려 있는:
$39.12
하루 거래량:
13,290
Relative Volume:
0.11
시가총액:
$423.27M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+4.66%
1개월 성능:
+53.76%
6개월 성능:
+146.21%
1년 성능:
+0.00%
1일 변동 폭
$37.33
$39.13
1주일 범위
$34.57
$39.40
52주 변동 폭
$11.17
$40.50
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
125 STRAFFORD AVE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
38.28 | 414.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.78 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.99 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.97 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.10 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.30 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Q2 2025 Earnings Call Scheduled for August 14 | PVLA Stock News - Stock Titan
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Palvella Therapeutics Inc. stock volume spike explainedGrowth Watchlist for Long Term Positioning - Newser
Analysts Set Expectations for PVLA Q2 Earnings - Defense World
How to read the order book for Palvella Therapeutics Inc.AI Trade Signal Forecast with Chart Logic - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockCapital Growth Plan for New Investors - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyHigh Yield Signals with Entry Timing - Newser
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
What institutional flow reveals about Palvella Therapeutics Inc.Predictive Analytics for Equity Growth Potential - Newser
Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
What indicators show strength in Palvella Therapeutics Inc.Weekly Outlook for Short Term Investors - Newser
Palvella Therapeutics Inc. stock trend forecastAI Intraday Market Movement Prediction Tool - Newser
Raymond James Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
Raymond James initiates Palvella Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Palvella Therapeutics CEO to Share Rare Disease Pipeline Updates at Major Growth Conference - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Lifesci Capital - Defense World
Does Palvella Therapeutics Inc. fit your quant trading modelFree Real Trader Watchlist of Hot Stocks - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Free Daily Smart Money Movement Monitor - Newser
Palvella Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Plan for Oversold Reversal Stocks Released - metal.it
Analysts Initiate Coverage on Akero Therapeutics, AeroVironment, Wave Life Sciences, Palvella Therapeutics, and WeRide Inc. - AInvest
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Will Palvella Therapeutics Inc. stock split in the near futureFree Step-by-Step Stock Investment Guide - Newser
Real time scanner hits for Palvella Therapeutics Inc. explainedDaily Pattern Analysis with Return Forecast - Newser
Is it the right time to buy Palvella Therapeutics Inc. stockBuild wealth steadily with proven stock picks - Jammu Links News
Is Palvella Therapeutics Inc. stock overvalued or undervaluedAccess high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Palvella Therapeutics Inc. in the next 12 monthsUnlock steady growth with low-risk stocks - Jammu Links News
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsReal-Time Setup Summary with ROI Focus - Newser
When is Palvella Therapeutics Inc. stock expected to show significant growthFree Trend-Following Techniques - Jammu Links News
Should I hold or sell Palvella Therapeutics Inc. stock in 2025Outstanding capital returns - Jammu Links News
How strong is Palvella Therapeutics Inc. company’s balance sheetUnlock real-time trading signals for gains - Jammu Links News
Is Palvella Therapeutics Inc. a growth stock or a value stockCapitalize on emerging investment opportunities - Jammu Links News
What catalysts could drive Palvella Therapeutics Inc. stock higher in 2025Maximize returns with timely market signals - Jammu Links News
What is the risk reward ratio of investing in Palvella Therapeutics Inc. stockMaximize portfolio growth with expert advice - Jammu Links News
What analysts say about Palvella Therapeutics Inc. stockBuild a winning investment strategy - Jammu Links News
What institutional investors are buying Palvella Therapeutics Inc. stockDiscover the next big stock winners - Jammu Links News
What are the latest earnings results for Palvella Therapeutics Inc.Unstoppable investment returns - Jammu Links News
Tools to assess Palvella Therapeutics Inc.’s risk profileRisk Aware Trading Ideas with Alert Levels - Newser
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.28%
2.25%
자본화:
|
볼륨(24시간):